P4HTM: IHC Expression in Cancer and Radioligand Target Profile
P4HTM, prolyl 4-hydroxylase, transmembrane, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, P4HTM staining is highest in head and neck cancer (100% of samples positive), endometrial cancer (100% of samples positive) and breast cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).
Is P4HTM the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze P4HTM freeIs P4HTM a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in head and neck cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
P4HTM IHC staining by cancer type
Protein expression of P4HTM across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Head and Neck Cancer | 1.00 | High | 100% |
| Endometrial Cancer | 0.94 | High | 100% |
| Breast Cancer | 0.92 | High | 100% |
| Glioma | 0.88 | High | 100% |
| Liver Cancer | 0.87 | High | 100% |
| Skin Cancer | 0.86 | High | 100% |
| Melanoma | 0.86 | High | 100% |
| Lung Cancer | 0.85 | High | 100% |
| Colorectal Cancer | 0.83 | High | 100% |
| Thyroid Cancer | 0.83 | High | 100% |
| Pancreatic Cancer | 0.82 | High | 100% |
| Ovarian Cancer | 0.81 | High | 100% |
| Cervical Cancer | 0.80 | High | 100% |
| Gastric Cancer | 0.80 | High | 100% |
| Bladder Cancer | 0.78 | High | 100% |
| Neuroendocrine Tumors | 0.75 | High | 100% |
| Prostate Cancer | 0.67 | High | 89% |
| Lymphoma | 0.56 | High | 75% |
| Testicular Cancer | 0.50 | Medium | 100% |
| Kidney Cancer | 0.25 | Medium | 50% |
Is P4HTM internalized?
Nuclens has not yet extracted internalization evidence for P4HTM. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
P4HTM clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for P4HTM yet. Search ClinicalTrials.gov for P4HTM trials.
P4HTM normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See P4HTM in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
P4HTM gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.14 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related head and neck cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · HER2 (ERBB2)
See all radioligand therapy targets in head and neck cancer.
See how P4HTM ranks against 15,000 targets for your indication.
Analyze P4HTM freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.